These results demonstrated miR-206 inhibited c-Met and Bcl2 expression in A549 cells, and loss of miR-206 would be attributed to the over-expression of c-Met and Bcl2 in lung cancer cells, which were the risks of NSCLS. This evidence concerns the gene BCL2 and lung carcinoma.